Stockscreener 앱 받기
4.12
2.83%
-0.12
전일 마감가:
$4.24
열려 있는:
$4.25
하루 거래량:
3.05M
Relative Volume:
1.76
시가총액:
$516.92M
수익:
$50.27M
순이익/손실:
$-68.91M
주가수익비율:
-6.8325
EPS:
-0.603
순현금흐름:
$-44.32M
1주 성능:
-1.44%
1개월 성능:
+3.26%
6개월 성능:
+5.37%
1년 성능:
+2.23%
1일 변동 폭
$4.00
$4.255
1주일 범위
$4.00
$4.38
52주 변동 폭
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.12 | 516.92M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - Investing News Network
2026-07-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
AQSTAquestive Therapeutics Inc Short Interest - Finviz
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
SEC Form S-3 filed by Aquestive Therapeutics Inc. - Quantisnow
Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com - Investing.com India
Aquestive Therapeutics | S-3: Registration statement for specified transactions by certain issuers - Moomoo
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST) - TradingView
symbol__ Stock Quote Price and Forecast - CNN
AQST Forecast — Price Target — Prediction for 2027 - TradingView
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Aquestive Therapeutics director Julie Krop sells $125k in stock By Investing.com - Investing.com Nigeria
Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com - Investing.com Australia
Aquestive Therapeutics director Julie Krop sells $125k in stock - Investing.com
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out - ACCESS Newswire
Form 144 Aquestive Therapeutics For: 23 June By Investing.com - Investing.com Australia
Aquestive Therapeutics (AQST) reports Q1 loss, beats revenue estimates - MSN
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out | NDAQ:AQST | Press Release - Stockhouse
Does US manufacturing give drugmakers a speed edge? - Pharma Voice
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire
AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart - ChartMill
Aquestive Therapeutics (NYSE:AQST): What Insider Activity Reveals About Corporate Confidence - Kalkine Media
Have Aquestive Therapeutics Insiders Been Selling Stock? - simplywall.st
Aquestive Therapeutics Inc (AQST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey
Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aquestive Therapeutics Inc (AQST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aquestive Therapeutics Inc (AQST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aquestive Therapeutics CEO sells $104,010 in company stock By Investing.com - Investing.com Canada
Aquestive Therapeutics CEO sells $104,010 in company stock - Investing.com UK
Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.42%
0.81%
자본화:
|
볼륨(24시간):